India's Richest People 2026 edition · 1 director · Source: Hurun India
- #143 Mahima Datla & family ₹25,200 Cr
Revenue · FY 2025
₹67.68 Lakh
▼ 12% YoY
Net profit · FY 2025
₹11.42 Lakh
Net margin 16.9%
EBITDA · FY 2025
₹18.9 Lakh
EBITDA margin 27.9%
Authorised capital
₹6 Cr
Registered with MCA
Paid-up capital
₹5.01 Cr
Issued & subscribed
Satisfied charges
₹20 Cr
No open charges
Company age
15 yrs
Est. 2011
Employees · EPFO
2
Provident fund records
About Be Pharmaceuticals Private Limited
Data last updated:
Be Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Biological E Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 August 2011 and has been in existence for over 15 years.
Its director Mahima Datla and family are #143 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24100TG2011PTC148362. Its GSTIN is 02AAJCA8290J1ZI (Himachal Pradesh). The company holds 7 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹6 Cr and a paid-up capital of ₹5.01 Cr. It was formerly known as Akorn India Private Limited. It is led by directors including Rudaraju Anand Kumar and Mahipal Reddy Saddi.
Its last annual general meeting (AGM) was held on 18 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 18/1 & 3 Azamabad, Hyderabad, Telangana, India – 500020.
As per the financials filed for FY 2025, the company reported a revenue of ₹67.68 Lakh, a decline of 12% compared to the previous year. For the same year it recorded a net profit of ₹11.42 Lakh (net margin 16.9%) and EBITDA of ₹18.9 Lakh (EBITDA margin 27.9%). Revenue has declined at a compounded annual rate (CAGR) of 62% over three years and 20% over five years.
The company has about 2 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Akorn India. As per MCA filings, the company has satisfied charges of ₹20 Cr on record. Court records list 15 cases involving the company, including 14 filed by the company and 1 filed against it; 5 cases are pending. The company has 18 deals on record (11 rights issues, 5 funding rounds, 1 secondary share transfer), with disclosed funding of ₹419.12 Cr; the latest was in August 2020. The company has 12 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 109 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website akornindia.com.
Company details
CIN U24100TG2011PTC148362
Registration Number 148362
Incorporation Date 29 August 2011
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 18 September 2024
Date of Balance Sheet 31 March 2024
Parent Company Biological E Limited
Compliance Status Active Compliant
CIN history
Be Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24100TG2011PTC148362, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100TG2011PTC148362 | Current |
| U24100MH2011PTC221406 | Previous |
| U24100DL2011PTC262196 | Previous |
Recognitions & Rankings of Be Pharmaceuticals
Contact details
Be Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is akornindia.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address18/1 & 3 Azamabad, Hyderabad, Telangana, India – 500020
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Be Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Be Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Be Pharmaceuticals operates one associated brand: Akorn India. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Sterile pharmaceuticals are developed, manufactured, and marketed by Akorn India. | akornindia.com |
Business activity
The main business activity of Be Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Be Pharmaceuticals Private Limited, buy the company report.
Financials of Be Pharmaceuticals Private Limited
FY 2024 filings availableBe Pharmaceuticals Private Limited reported revenue of ₹67.68 Lakh (down 12% YoY) for FY 2025.
Revenue · FY 2025
₹67.68 Lakh ▼ 12%
Net profit · FY 2025
₹11.42 Lakh margin 16.9%
EBITDA · FY 2025
₹18.9 Lakh margin 27.9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 12%
3 years · compounded
▼ 62%
5 years · compounded
▼ 20%
EBITDA CAGR growth
1 year
▲ 57%
3 years · compounded
▲ 26%
5 years · compounded
▲ 15%
Revenue has declined at a compounded annual rate (CAGR) of 20% over five years, including a 12% fall in the latest year. EBITDA rose 57% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹18.9 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹11.42 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 27.9% | ||||
| Net Profit Margin | 16.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Be Pharmaceuticals Private Limited, buy the company report.
Board of directors of Be Pharmaceuticals Private Limited
Be Pharmaceuticals has 3 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rudaraju Anand Kumar Also directs: Biological E. Limited, Biotech Medicals Private Limited, Lacto-Cosmetics (Hyd) Pvt Ltd and 5 more | Director | 14 Aug 2020 | 6 Years 2 Months | Current |
| Mahipal Reddy Saddi | Director | 26 Aug 2020 | 6 Years 2 Months | Current |
| Mahima Datla | Director | 14 Aug 2020 | 6 Years 2 Months | Current |
Auditor
Be Pharmaceuticals Private Limited is audited by DAT LA & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DAT LA & ASSOCIATES | FY 2024 | 012185S |
Shareholding
The shareholding of Be Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Be Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹20 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Jul 2014 | 10522225 | Icici Bank Limited | ₹20 Cr | Satisfied |
To see the full charge records of Be Pharmaceuticals Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Be Pharmaceuticals Private Limited has 18 deals on record (11 rights issues, 5 funding rounds, 1 secondary share transfer), with disclosed funding of ₹419.12 Cr; the latest was in August 2020.
Total deals
18
Rights issues
11
Funding rounds
5
Secondary share transfer
1
Acquisition
1
Disclosed funding
₹419.12 Cr
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2020 | Acquisition | Undisclosed | Buyer: Biological E. Limited |
| Jul 2020 | Funding round | ₹5.77 Cr | Investors: World Akorn Pharma Mauritius |
| Nov 2019 | Rights issue | ₹9.04 Cr | Investors: World Akorn Pharma Mauritius |
| Sep 2019 | Rights issue | ₹8.85 Cr | Investors: World Akorn Pharma Mauritius |
| Mar 2019 | Rights issue | ₹35 Cr | Investors: World Akorn Pharma Mauritius |
To see the full deal history of Be Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Be Pharmaceuticals Private Limited has 15 court cases on record: 14 filed by Be Pharmaceuticals, 1 filed against it. 5 cases are pending and 10 are disposed.
Total cases
15
Filed by the company
14
Filed against the company
1
Pending
5
Disposed
10
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 8 | 1 | 1 |
| High courts | 5 | 0 | 4 |
| NCLT | 2 | 0 | 0 |
Cases on record (5 of 15)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Sirmaur, Himachal Pradesh | Cheque dishonour complaint | Filed by the company against Vexta Laboratories Pvt Ltd | Disposed |
| High Court, HIMACHAL PRADESH | Writ petition | Filed by the company against Himachal Pradesh State Electricity Board Ltd. and 4 others | Disposed |
| High Court of Delhi | Tax appeal | Filed by the company against Deputy Commissioner of Income-Tax, Circle 2(1), New Delhi | Pending |
| High Court of Delhi | Tax appeal | Filed by the company against Assistant Commissioner of Income-Tax, Circle 2(1), New Delhi | Pending |
| District court, Sirmaur, Himachal Pradesh | Court case (Payment Of Wages Act) | Filed against the company by an individual | Pending |
To see the full case history of Be Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Be Pharmaceuticals Private Limited has 12 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 109 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 109)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ito Precision Technologies Private Limited | |||
| Netsquare Automation Private Limited | |||
| Aimil Limited | |||
| Biologic | |||
| Kaisha Packaging Private Limited |
To see the full MSME payment records of Be Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Be Pharmaceuticals Private Limited has a workforce of 2 employees on its EPFO records as of May 2026, across 3 active EPFO establishments.
Employee count
2
Active EPFO establishments
3
Employee growth
-33.3%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 2 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Be Pharmaceuticals Private Limited, buy the company report.
GST
Be Pharmaceuticals has 7 GST registrations: 1 active and 6 cancelled or inactive.
Total GSTINs
7
Active
1
Cancelled / inactive
6
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AAJCA8290J1ZI | Himachal Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Be Pharmaceuticals Private Limited, buy the company report.
Recent activity
Be Pharmaceuticals Private Limited has 18 board changes on record since 2011: 3 appointments and 15 cessations. The latest: Mahipal Reddy Saddi ceased to be Additional Director on 04 Sep 2020.
AGM
Be Pharmaceuticals Private Limited last Annual general meeting of members was held on 18 Sep 2024 as per latest MCA records.
Filing
Be Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Ceased
Mahipal Reddy Saddi ceased to be Additional Director.
Appointed
Mahipal Reddy Saddi was appointed as Director.
Ceased
Mahima Datla ceased to be Additional Director.
Ceased
Rudaraju Anand Kumar ceased to be Additional Director.
Ceased
Dheeraj Chopra ceased to be Whole-Time Director.
Ceased
Joseph Patrick Bonaccorsi ceased to be Director.
Appointed
Mahima Datla was appointed as Director.
Appointed
Rudaraju Anand Kumar was appointed as Director.
Ceased
John Anthony Valley ceased to be Additional Director.
Ceased
Scott Eric Wagner ceased to be Director.
11 earlier events are in the company report.
News
Frequently asked questions
Be Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 August 2011 (15+ years old) and is registered under CIN U24100TG2011PTC148362.
Be Pharmaceuticals has 3 current directors:
- Rudaraju Anand Kumar - Director
- Mahipal Reddy Saddi - Director
- Mahima Datla - Director
The latest financial statements of Be Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 18 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Be Pharmaceuticals is 02AAJCA8290J1ZI, registered in Himachal Pradesh. The company has 7 GST registrations in all, of which 1 is active and 6 are cancelled or inactive.
The CIN (Corporate Identification Number) of Be Pharmaceuticals is U24100TG2011PTC148362. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Be Pharmaceuticals has 15 court cases on record: 14 filed by the company and 1 filed against it. 5 are pending. Most are in the district courts.
Be Pharmaceuticals was incorporated on 29 August 2011, making it 15+ years old. It is registered with the Registrar of Companies, Hyderabad.
Be Pharmaceuticals has 18 deals on record (11 rights issues, 5 funding rounds, 1 secondary share transfer), with disclosed funding of ₹419.12 Cr; the latest was in August 2020.
Mahipal Reddy Saddi ceased to be Additional Director on 04 Sep 2020. Mahipal Reddy Saddi was appointed as Director on 26 Aug 2020. Mahima Datla ceased to be Additional Director on 17 Aug 2020. Be Pharmaceuticals has 18 board changes on record in total.
Be Pharmaceuticals has 12 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 109 micro and small suppliers. The latest return was filed on 05 May 2023.
Be Pharmaceuticals can be reached through the website akornindia.com. Its registered office is in Hyderabad, Telangana, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages